On April 17, 2025, X4 Pharmaceuticals held a special meeting where stockholders voted to approve a reverse stock split of their common stock, with 113,027,737 shares in favor out of 137,240,628 shares present. The split will combine shares at a ratio between one-for-fifteen and one-for-thirty, as determined by the board.